臨床試驗

ELISA in Relapsed/Refractory MM

NCT：NCT06832865 · RECRUITING

NCT IDNCT06832865

狀態RECRUITING

開始日期2025-08-14

完成時間2028-12-01

SponsorMassachusetts General Hospital (OTHER)

First posted2025-02-18

Last updated2026-09-16

簡要摘要

This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at least one prior line of therapy and who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI). The subcutaneous injection method of isatuximab administration, including the device used to administer isatuximab, is investigational.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。